Drug Type TCR therapy |
Synonyms HERV Targeted TCR-T (T-Cure Bioscience), 800 TCR, 800-TCR |
Target |
Mechanism ERVE-1 modulators(endogenous retrovirus group E member 1 modulators), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization T-Cure Bioscience, Inc.Startup |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Kidney Neoplasms | Phase 1 | US | T-Cure Bioscience, Inc.Startup | 04 Aug 2020 |
Metastatic Clear Cell Renal Cell Carcinoma | Phase 1 | US | 20 Jul 2018 |
Phase 1 | 17 | IL-2 (aldesleukin)+fludarabine+cyclophosphamide (Level 1: 1 x 10^6 HERV-E TCR Transduced CD8+/CD34+ Enriched T-cells Per kg Body Weight) | ldjbkuzmom(ghguynhpdp) = vcppdkzkuy kpjrevxgss (itcvntemkg, plxlvblmdv - fwdsisygwz) View more | - | 03 Dec 2024 | ||
IL-2 (aldesleukin)+fludarabine+cyclophosphamide (Level 2: 5 x 10^6 HERV-E TCR Transduced CD8+/CD34+ Enriched T-cells Per kg Body Weight) | ldjbkuzmom(ghguynhpdp) = uejvdbxunm kpjrevxgss (itcvntemkg, ukwrmhsgsa - ucqlzqcoth) View more |